Haseeb Abdul, Siddiqui Ali, Taylor Linda J, Mills Alyssa, Kowalski Thomas E, Loren David E, Dahmus Jessica, Yalamanchili Silpa, Cao Christopher, Canakis Andrew, Mumtaz Tayebah, Parikh Meet, Adler Douglas G
Division of Gastroenterology, School of Medicine, University of Utah, Salt Lake City, UT, USA.
Division of Gastroenterology, School of Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
Minerva Gastroenterol Dietol. 2018 Jun;64(2):111-116. doi: 10.23736/S1121-421X.17.02428-X. Epub 2017 Sep 5.
Fully-covered self-expandable metal stents (FCSEMS) have been used in benign biliary diseases although reported data is limited. These devices are most commonly used to treat biliary leaks, strictures, or both. The aim of this study was to evaluate effectiveness of FCSEMS in treating benign biliary disease and recognize the associated complications.
We performed a multicenter longitudinal retrospective cohort study of patients with benign biliary disease needing FCSEMS between 2011 and 2016. Descriptive statistics were performed using SPSS version 24 (SPSS Inc, Chicago, IL, USA) and continuous variables were presented as mean±standard deviation.
75, 57% M/43% F, with a mean age of 58.5±14.9 years, were included. 64 (85%) had benign strictures, 7 patients had leaks, and 4 patients had both a leak and a stricture. Chronic pancreatitis was the most common cause of BBS (47%) and cholecystectomy was the most common cause of leaks. FCSEMS placement was technically successful in all patients. Four patients died of unrelated causes. A recurrent stricture was observed in 24 (32%) of the patients. Recurrent strictures were most commonly seen in patients with chronic pancreatitis 12/35 (34%). Stent migration occurred in 8/75 patients (10.7%). Seven patients (9.3%) had adverse events, acute pancreatitis (N.=4) was most common.
FCSEMS are safe and effective for treating biliary strictures and leaks. We report decreased rates of stent migration compared to previous studies. Prospective studies are needed to compare plastic stents with FCSEMS, determine optimal stent in-dwell times and cost effectiveness of FCSEMS.
全覆膜自膨式金属支架(FCSEMS)已用于良性胆道疾病,尽管相关报道数据有限。这些装置最常用于治疗胆漏、胆管狭窄或两者皆有。本研究的目的是评估FCSEMS治疗良性胆道疾病的有效性,并识别相关并发症。
我们对2011年至2016年间需要FCSEMS的良性胆道疾病患者进行了一项多中心纵向回顾性队列研究。使用SPSS 24版(美国伊利诺伊州芝加哥市SPSS公司)进行描述性统计,连续变量以均值±标准差表示。
共纳入75例患者,男性占57%(43例),女性占43%(32例),平均年龄为58.5±14.9岁。64例(85%)有良性狭窄,7例有胆漏,4例既有胆漏又有狭窄。慢性胰腺炎是良性胆管狭窄最常见的原因(47%),胆囊切除术是胆漏最常见的原因。FCSEMS置入在所有患者中技术上均获成功。4例患者死于无关原因。24例(32%)患者出现复发性狭窄。复发性狭窄最常见于慢性胰腺炎患者,12/35例(34%)。8/75例患者(10.7%)发生支架移位。7例患者(9.3%)出现不良事件,最常见的是急性胰腺炎(4例)。
FCSEMS治疗胆管狭窄和胆漏安全有效。与既往研究相比,我们报道的支架移位率有所降低。需要进行前瞻性研究以比较塑料支架与FCSEMS,确定FCSEMS的最佳支架留置时间和成本效益。